Arbutin promotes MC3T3‑E1 mouse osteoblast precursor cell proliferation and differentiation via the Wnt/β‑catenin signaling pathway

Man,Xiangji; Yang,Liyu; Liu,Shengye; Yang,Lei; Li,Mingyang; Fu,Qin

doi:10.3892/mmr.2019.10125

Arbutin promotes MC3T3‑E1 mouse osteoblast precursor cell proliferation and differentiation via the Wnt/β‑catenin signaling pathway

Authors:
- Xiangji Man
- Liyu Yang
- Shengye Liu
- Lei Yang
- Mingyang Li
- Qin Fu
View Affiliations

Affiliations: Department of Orthopedic Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China
Published online on: April 4, 2019 https://doi.org/10.3892/mmr.2019.10125
Pages: 4637-4644
Copyright: © Man et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arbutin is a natural compound extracted from various plants, including bearberry leaves, that exerts multiple effects including skin whitening, anti‑inflammatory and oxidative stress‑protective properties. However, the effects of arbutin on osteoblasts remain unknown. The aim of the present study was to investigate the function and the mechanisms of arbutin on the proliferation and differentiation of MC3T3‑E1 mouse osteoblast precursor cells in vitro. The proliferation of MC3T3‑E1 cells treated with arbutin was assessed using a Cell Counting Kit‑8 assay and a 5‑ethynyl‑2'‑deoxyuridine labeling assay. Additionally, cell cycle and apoptosis were examined using flow cytometry analysis. The effects of arbutin on osteoblast differentiation were investigated using alkaline phosphatase (ALP) staining and by examining the mRNA expression levels of collagen type I α1 chain (COL1A1), bone γ‑carboxyglutamate protein (BGLAP) and Sp7 transcription factor (SP7). To further investigate the molecular mechanism underlying arbutin function in promoting osteogenesis, the mRNA and protein expression levels of runt‑related transcription factor 2 (RUNX2) and β‑catenin were analyzed by reverse transcription‑quantitative polymerase chain reaction and western blotting. Arbutin significantly promoted MC3T3‑E1 cell proliferation and increased the ratio of cells in S‑phase. Treatment with arbutin increased ALP activity and the mRNA expression levels of COL1A1, BGLAP and SP7 in MC3T3‑E1 cells. Furthermore, the protein and the mRNA expression levels of RUNX2 and β‑catenin increased significantly following treatment with arbutin. Collectively, the present findings suggested that arbutin was able to promote proliferation and differentiation of MC3T3‑E1 cells via the Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Das S and Crockett JC: Osteoporosis-a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 7:435–448. 2013.PubMed/NCBI
2	Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B and Kanis JA: Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA). Arch Osteoporos. 8:1362013. View Article : Google Scholar : PubMed/NCBI
4	Cauley JA: Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 68:1243–1251. 2013. View Article : Google Scholar : PubMed/NCBI
5	Manolagas SC and Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 332:305–311. 1995. View Article : Google Scholar : PubMed/NCBI
6	Baron R and Hesse E: Update on bone anabolics in osteoporosis treatment: Rationale, current status, and perspectives. J Clin Endocrinol Metab. 97:311–325. 2012. View Article : Google Scholar : PubMed/NCBI
7	Tang DZ, Hou W, Zhou Q, Zhang M, Holz J, Sheu TJ, Li TF, Cheng SD, Shi Q, Harris SE, et al: Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res. 25:1234–1245. 2010. View Article : Google Scholar : PubMed/NCBI
8	Canalis E: Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab. 95:1496–1504. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lamien-Meda A, Lukas B, Schmiderer C, Franz C and Novak J: Validation of a quantitative assay of arbutin using gas chromatography in Origanum majorana and Arctostaphylos uva-ursi extracts. Phytochem Anal. 20:416–420. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lim YJ, Lee EH, Kang TH, Ha SK, Oh MS, Kim SM, Yoon TJ, Kang C, Park JH and Kim SY: Inhibitory effects of arbutin on melanin biosynthesis of alpha-melanocyte stimulating hormone-induced hyperpigmentation in cultured brownish guinea pig skin tissues. Arch Pharm Res. 32:367–373. 2009. View Article : Google Scholar : PubMed/NCBI
11	Maeda K and Fukuda M: Arbutin: Mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 276:765–769. 1996.PubMed/NCBI
12	Wu LH, Li P, Zhao QL, Piao JL, Jiao YF, Kadowaki M and Kondo T: Arbutin, an intracellular hydroxyl radical scavenger, protects radiation-induced apoptosis in human lymphoma U937 cells. Apoptosis. 19:1654–1663. 2014. View Article : Google Scholar : PubMed/NCBI
13	Omori A, Yoshimura Y, Deyama Y and Suzuki K: Rosmarinic acid and arbutin suppress osteoclast differentiation by inhibiting superoxide and NFATc1 downregulation in RAW 264.7 cells. Biomed Rep. 3:483–490. 2015. View Article : Google Scholar : PubMed/NCBI
14	Baron R and Kneissel M: WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med. 19:179–192. 2013. View Article : Google Scholar : PubMed/NCBI
15	Baron R and Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 148:2635–2643. 2007. View Article : Google Scholar : PubMed/NCBI
16	Hoeppner LH, Secreto FJ and Westendorf JJ: Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 13:485–496. 2009. View Article : Google Scholar : PubMed/NCBI
17	Williams BO and Insogna KL: Where Wnts went: The exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 24:171–178. 2009. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Lin X, Xiong D, Peng YQ, Sheng ZF, Wu XY, Wu XP, Wu F, Yuan LQ and Liao EY: Epidemiology and management of osteoporosis in the People's Republic of China: Current perspectives. Clin Interv Aging. 10:1017–1033. 2015.PubMed/NCBI
20	Manolagas SC: Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 21:115–137. 2000. View Article : Google Scholar : PubMed/NCBI
21	Liu S, Fang T, Yang L, Chen Z, Mu S and Fu Q: Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the NRF2 signaling pathway. Int J Mol Med. 41:2059–2069. 2018.PubMed/NCBI
22	Yun HM, Park KR, Quang TH, Oh H, Hong JT, Kim YC and Kim EC: 2,4,5-Trimethoxyldalbergiquinol promotes osteoblastic differentiation and mineralization via the BMP and Wnt/β-catenin pathway. Cell Death Dis. 6:e18192015. View Article : Google Scholar : PubMed/NCBI
23	Cosman F, Nieves JW and Dempster DW: Treatment sequence matters: Anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 32:198–202. 2017. View Article : Google Scholar : PubMed/NCBI
24	Uihlein AV and Leder BZ: Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am. 41:507–525. 2012. View Article : Google Scholar : PubMed/NCBI
25	Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, et al: Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 97:3097–3106. 2012. View Article : Google Scholar : PubMed/NCBI
26	Jurica K, Brčić Karačonji I, Mikolić A, Milojković-Opsenica D, Benković V and Kopjar N: In vitro safety assessment of the strawberry tree (Arbutus unedo L.) water leaf extract and arbutin in human peripheral blood lymphocytes. Cytotechnology. 70:1261–1278. 2018. View Article : Google Scholar : PubMed/NCBI
27	Schindler G, Patzak U, Brinkhaus B, von Niecieck A, Wittig J, Krähmer N, Glöckl I and Veit M: Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. J Clin Pharmacol. 42:920–927. 2002. View Article : Google Scholar : PubMed/NCBI
28	Genovese C, Davinelli S, Mangano K, Tempera G, Nicolosi D, Corsello S, Vergalito F, Tartaglia E, Scapagnini G and Di Marco R: Effects of a new combination of plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. J Chemother. 30:107–114. 2018. View Article : Google Scholar : PubMed/NCBI
29	Lee HJ and Kim KW: Anti-inflammatory effects of arbutin in lipopolysaccharide-stimulated BV2 microglial cells. Inflamm Res. 61:817–825. 2012. View Article : Google Scholar : PubMed/NCBI
30	Jiang L and Wang D, Zhang Y, Li J, Wu Z, Wang Z and Wang D: Investigation of the pro-apoptotic effects of arbutin and its acetylated derivative on murine melanoma cells. Int J Mol Med. 41:1048–1054. 2018.PubMed/NCBI
31	Marie PJ and Kassem M: Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets. Eur J Endocrinol. 165:1–10. 2011. View Article : Google Scholar : PubMed/NCBI
32	Canalis E: Management of endocrine disease: Novel anabolic treatments for osteoporosis. Eur J Endocrinol. 178:R33–R44. 2018. View Article : Google Scholar : PubMed/NCBI
33	Weinreb M, Shinar D and Rodan GA: Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res. 5:831–842. 1990. View Article : Google Scholar : PubMed/NCBI
34	Kim YJ, Lee MH, Wozney JM, Cho JY and Ryoo HM: Bone morphogenetic protein-2-induced alkaline phosphatase expression is stimulated by Dlx5 and repressed by Msx2. J Biol Chem. 279:50773–50780. 2004. View Article : Google Scholar : PubMed/NCBI
35	An J, Yang H, Zhang Q, Liu C, Zhao J, Zhang L and Chen B: Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 147:46–58. 2016. View Article : Google Scholar : PubMed/NCBI
36	Kobayashi T and Kronenberg H: Minireview: Transcriptional regulation in development of bone. Endocrinology. 146:1012–1017. 2005. View Article : Google Scholar : PubMed/NCBI
37	Alford AI, Golicz AZ, Cathey AL and Reddy AB: Thrombospondin-2 facilitates assembly of a type-I collagen-rich matrix in marrow stromal cells undergoing osteoblastic differentiation. Connect Tissue Res. 54:275–282. 2013. View Article : Google Scholar : PubMed/NCBI
38	Neve A, Corrado A and Cantatore FP: Osteocalcin: Skeletal and extra-skeletal effects. J Cell Physiol. 228:1149–1153. 2013. View Article : Google Scholar : PubMed/NCBI
39	Wang Y, Li YP, Paulson C, Shao JZ, Zhang X, Wu M and Chen W: Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed). 19:379–407. 2014. View Article : Google Scholar : PubMed/NCBI
40	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
41	Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF and Kneissel M: Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 30:3071–3085. 2010. View Article : Google Scholar : PubMed/NCBI
42	Ducy P, Schinke T and Karsenty G: The osteoblast: A sophisticated fibroblast under central surveillance. Science. 289:1501–1504. 2000. View Article : Google Scholar : PubMed/NCBI
43	Franceschi RT and Xiao G: Regulation of the osteoblast-specific transcription factor, RUNX2: Responsiveness to multiple signal transduction pathways. J Cell Biochem. 88:446–454. 2003. View Article : Google Scholar : PubMed/NCBI
44	Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 280:33132–33140. 2005. View Article : Google Scholar : PubMed/NCBI
45	Kawano Y and Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 116:2627–2634. 2003. View Article : Google Scholar : PubMed/NCBI
46	Daoussis D and Andonopoulos AP: The emerging role of Dickkopf-1 in bone biology: Is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum. 41:170–177. 2011. View Article : Google Scholar : PubMed/NCBI
47	Taurin S, Sandbo N, Qin Y, Browning D and Dulin NO: Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 281:9971–9976. 2006. View Article : Google Scholar : PubMed/NCBI